论文部分内容阅读
采用人结肠癌裸鼠腹腔种植瘤模型，进行表阿霉素早期和延期腹腔内化疗，观察其对癌细胞腹腔内种植的影响。15只雄性裸鼠腹腔内接种Lovo细胞后，随机分成对照组、早期和延期腹腔内化疗3组。早期腹腔内化疗组以0．8mg/kg/d表阿霉素于接种后1～3天行腹腔注射，延期组用相同剂量于接种后5～7天行腹腔注射。结果显示，早期腹腔内化疗组裸鼠平均荷瘤生存时间最长；延期腹腔内化疗组次之；对照组最短。前者与后两者比较，均有显著性差异（P＜0．05和P＜0．01）。实验提示早期腹腔内化疗的抑瘤作用明显高于延期腹腔内化疗。
The model of human colon cancer nude mice implanted in the abdominal cavity was used to perform early and delayed intraperitoneal chemotherapy of epirubicin to observe the effect on the intraperitoneal implantation of cancer cells. Fifteen male nude mice were inoculated intraperitoneally with Lovo cells and randomly divided into control group, early and delayed intraperitoneal chemotherapy 3 groups. In the early intraperitoneal chemotherapy group, 0.8 mg/kg/d epirubicin was intraperitoneally injected 1 to 3 days after inoculation, and the delayed group was intraperitoneally injected at the same dose 5 to 7 days after inoculation. The results showed that in the early intraperitoneal chemotherapy group, the average tumor survival time was the longest in the nude mice, followed by the delayed intraperitoneal chemotherapy group, and the shortest in the control group. The former was significantly different from the latter two (P<0.05 and P<0.01). The experiment suggests that the anti-tumor effect of early intraperitoneal chemotherapy is significantly higher than that of delayed intraperitoneal chemotherapy.